Experimental immune cell therapy for liver cancer hits early roadblock
NCT ID NCT04502082
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This early-stage trial tested a new type of immune cell therapy (ET140203 T cells) in 8 adults with advanced liver cancer that had not responded to other treatments. The therapy was designed to target a protein called AFP found on cancer cells. The study was terminated early, so we have very limited information on safety or effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
engineered immune cells (ET140203 T cells)
What this could lead to
If this approach had worked, it could have pointed toward a new treatment option for people with advanced liver cancer who have run out of standard therapies.
What could go wrong
This was a very early, small trial that was terminated before completion. The therapy may not be effective or safe enough, and it is unclear if it will ever be tested further.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LIVER CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Kansas University Medical Center
Westwood, Kansas, 66205, United States